Lercanidipina Pentafarma (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in arterial smooth muscle. By preventing calcium entry, it promotes vasodilation of peripheral arteries, decreasing systemic vascular resistance and consequently lowering systolic and diastolic blood pressure without significantly affecting heart rate.

The appropriate dose of lercanidipine is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Dosage adjustments are made individually; patients should follow the prescriber’s instructions precisely.

Safety data for lercanidipine in pregnancy are limited, and the drug is generally avoided unless the potential benefit justifies the risk. It is also not recommended during breastfeeding because it may pass into breast milk. Consultation with a healthcare professional is essential before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercanidipine, a dihydropyridine calcium‑channel blocker, primarily induces arterial vasodilation, whereas ACE inhibitors reduce angiotensin‑II formation and beta‑blockers decrease cardiac output. Lercanidipine often provides a smoother blood‑pressure profile with fewer reflex tachycardia episodes compared with some older calcium‑channel blockers.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat, and direct sunlight. Do not refrigerate or freeze the product.

Lercanidipina Pentafarma is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, though rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as angioedema, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe dizziness, or swelling of the face or throat.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without dose adjustment. Clinicians must evaluate each patient’s medical history before prescribing.